Two Confirmed Statin Failures: Choosing Between an Injection and a Pill
A statin-intolerant woman with prior myocardial infarction and persistent LDL elevation on ezetimibe, choosing between a more potent injectable PCSK9 inhibitor and a less potent, better-tolerated oral bempedoic acid.
Paula H., a 63-year-old competitive ballroom dancer who alters her own performance costumes on a machine older than her youngest student, had her cardiology follow-up interrupted twice this year by the same conversation: her LDL is still too high, and the drug class built to fix it keeps taking her legs out from under her, literally, mid-routine. Two years ago she had an NSTEMI, treated with a drug-eluting stent to a mid-LAD lesion, and has been chasing a stable statin regimen ever since without success. She competes at the regional level and has quietly started structuring her training around whichever weeks she happens to feel strong, rather than a fixed schedule, which her cardiologist reads as a patient already adapting her life around a drug problem nobody has actually solved yet.
The intolerance itself isn't ambiguous the way statin-associated symptoms sometimes are. Atorvastatin produced diffuse thigh and calf pain within six weeks alongside a creatine kinase that climbed to 1,400 IU/L against her own baseline of roughly 90; both resolved within a month of stopping. A deliberate rechallenge with rosuvastatin, at her cardiologist's insistence rather than her own, reproduced the same pattern — pain first, then a CK rise to 1,150 IU/L — which is the kind of objective, biomarker-confirmed recurrence that separates true statin myopathy from the symptom-only intolerance that blinded n-of-1 rechallenge trials — SAMSON and StatinWISE both — found was largely not reproducible in the patients reporting it. Maximum-tolerated ezetimibe brought her LDL from 210 down to 145, a real but insufficient improvement given her existing coronary disease, and today's visit is about what closes the rest of that gap without asking her to gamble a third time on a drug class that has twice put a number on exactly why she was right to be worried.
In follow-up, choosing what fills the gap
Evolocumab, not bempedoic acid. Her LDL is still 145 on maximum-tolerated ezetimibe and she has established disease — a prior NSTEMI two years ago — which puts her in exactly the population FOURIER studied. A PCSK9 monoclonal antibody drops LDL by roughly 55 to 60 percent from baseline, genuinely more than bempedoic acid's roughly 20 percent reduction on top of statin or ezetimibe therapy seen in CLEAR Outcomes, and with her risk profile, the size of the drop matters.
Two documented creatine kinase elevations across two different statins already settled whether her intolerance is real — that isn't what's being argued here, only what to do about the LDL that's left.
The potency argument is real, but it isn't the only variable that determines whether a patient actually stays on a drug for the next twenty years. Bempedoic acid is a once-daily pill; evolocumab is a self-injection every two to four weeks that a meaningful fraction of patients quietly stop refilling once the novelty wears off, and CLEAR Outcomes still showed a genuine 13% relative reduction in the composite cardiovascular endpoint in statin-intolerant patients despite the smaller LDL drop.
A bigger LDL reduction on paper that a patient doesn't sustain isn't actually the bigger reduction — adherence is part of the pharmacology here, not a separate practical afterthought layered on top of it.
That's fair, and it's the real reason I'd put a floor under how strongly I'd push evolocumab if I thought she'd struggle with the injection itself — but nothing in her history suggests that. She's independent, mechanically confident enough to alter her own dance costumes, and has said outright she'd rather take the more effective option even if it's an injection. Given that, and given how far above target she still sits, I'd still start with the drug that gets her there faster.
Bempedoic acid's own signal for gout and cholelithiasis is worth naming directly, not folded into a side-effect footnote — ACL inhibition raises serum uric acid by a mechanism distinct from anything statins do, and it's not nothing in a patient we're already asking to tolerate a new daily medication.
Agreed: start evolocumab alongside her continued ezetimibe, with LDL rechecked at 12 weeks. Paula's own stated preference — that she'd rather take the more effective option even as an injection — was treated by both physicians as a legitimate, load-bearing part of the decision, not just a tiebreaker.
Not fully agreed: how quickly to move to bempedoic acid if injection adherence turns out to be harder in practice than Paula expects. The preventive cardiologist would switch after a single missed dose reported at follow-up; the pharmacologist would want a clearer pattern of non-adherence first, worried that switching too readily on the first hiccup undersells a drug that, correctly used, would get her further from goal.